IRCT2015051222234N1已完成未知
Evaluation of the immunogenicity and safty of thepentavalent vaccine used in national immunization programcompared with the same vaccines from the otherpharmaceutical companies
ational Institute for Medical Research Development0 个研究点目标入组 1,200 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 1,200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 2 months 至 7 months（—）
- 性别
- All
入选标准
- •1.Healthy 2 -month-old infant boy or girl who is referred for routine vaccination
- •2.Infant disease is not identified at the time of visit
- •3.Upon arriving at the physical examination is normal nursing
- •4.Parents of infants in the study were successful login and sign the informed consent form
- •5.infants with gestational age of 38 weeks of a normal pregnancy and birth weight = 2.5 kg
- •Exclusion criteria:
- •1.The use of any vaccine or drug, vaccine research studies except during the study period or 30 days prior to study entry
- •2.History of blood transfusions or blood products or immunoglobulin consumption
- •3.History of heart, respiratory, kidney, liver and blood disease
- •4.Known genetic or congenital immune deficiency
- •5.Participation in other clinical studies
排除标准
- 未提供
研究者
相似试验
已完成
不适用
Evaluation of a prototype vaccine against enterotoxigenic Escherichia coli diarrhoeaEnterotoxigenic E. coli (ETEC) diarrhoeaInfections and InfestationsEnterotoxigenic Escherichia coli infectionISRCTN23764070Gothenburg University Vaccine Research Institute (GUVAX) (Sweden)60
已完成
1 期
Reactogenicity and Immunogenicity of the pentavalent vaccine DPT-HB+Hib. Schedule 2-4-6 months.Prophylaxis against infections diseases: Diphtheria, Tetanus, B. pertussis, H. influenzae type b and hepatitis B.RPCEC00000103Center for Genetic Engineering and Biotechnology (CIGB).624
尚未招募
1 期
ABDALA Clinical StudyCOVID-19SARS-CoV2Disease PreventionCoronavirus InfectionsSARS VirusCoronaviridae InfectionsBetacoronavirusRPCEC00000346Center for Genetic Engineering and Biotechnology (CIGB), in Havana
尚未招募
1 期
Safety and immunogenicity of VCN7-T in infants of 2 and 3 months. Phase I/II.Pneumococcal diseaseHealthy VolunteersPneumococcal InfectionsStreptococcal InfectionsGram-Positive Bacterial InfectionsRPCEC00000243Finlay Institute Vaccine880
已完成
不适用
Assessment of the immunogenicity and safety of the Northern Hemisphere 2010/2011-season influenza vaccine in elderly and young subjects according to European Medicines Agency (EMEA) regulationsInfluenzaISRCTN89337058Crucell Switzerland AG (Switzerland)110